Paratek Pharmaceuticals Inc (PRTK) Analysts See $-0.93 EPS

October 13, 2017 - By Hazel Jackson

 Paratek Pharmaceuticals Inc (PRTK) Analysts See $ 0.93 EPS
Investors sentiment decreased to 1.89 in 2017 Q2. Its down 0.15, from 2.04 in 2017Q1. It is negative, as 13 investors sold Paratek Pharmaceuticals Inc shares while 23 reduced holdings. 28 funds opened positions while 40 raised stakes. 19.26 million shares or 15.88% more from 16.62 million shares in 2017Q1 were reported.
State Street invested 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Moreover, Nicholas Inv Prtn L P has 0.35% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 204,009 shares. 16,191 are owned by Proshare Advsrs Lc. Fortress Investment Gru Ltd Com owns 0.21% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 433,804 shares. Columbus Circle Invsts stated it has 19,937 shares. Citadel Advsr Ltd holds 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 54,961 shares. New York State Common Retirement Fund holds 39,399 shares or 0% of its portfolio. 13,500 are owned by Levin Capital Strategies Limited Partnership. Parametric Port Associates Lc invested 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Financial Bank Of Mellon invested in 172,499 shares. Axiom Ltd Llc De invested 0.04% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). 14,705 were accumulated by Credit Suisse Ag. Balyasny Asset Mgmt Ltd Limited Liability Company reported 0.03% stake. Baupost Grp Ltd Liability Ma reported 2.39M shares stake. Zurcher Kantonalbank (Zurich Cantonalbank) holds 677 shares.

Wall Street await Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to release earnings on November, 1. Analysts forecast earnings per share of $-0.93, up exactly $0.11 or 10.58 % from 2014’s $-1.04 EPS. After posting $-0.64 EPS for the previous quarter, Paratek Pharmaceuticals Inc’s analysts now forecast 45.31 % negative EPS growth. It closed at $24.4 lastly. It is down 62.03% since October 13, 2016 and is uptrending. It has outperformed by 45.33% the S&P500.

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Ratings Coverage

Among 9 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Paratek Pharmaceuticals had 21 analyst reports since July 23, 2015 according to SRatingsIntel. Leerink Swann maintained the shares of PRTK in report on Tuesday, July 18 with “Buy” rating. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Buy” rating by Robert W. Baird on Thursday, September 21. As per Thursday, October 27, the company rating was reinitiated by Leerink Swann. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, August 23. As per Monday, July 17, the company rating was maintained by Cantor Fitzgerald. The company was upgraded on Wednesday, September 2 by Zacks. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, June 29 report. Leerink Swann maintained the shares of PRTK in report on Thursday, June 15 with “Buy” rating. The company was maintained on Wednesday, June 21 by Cantor Fitzgerald. Robert W. Baird initiated Paratek Pharmaceuticals Inc (NASDAQ:PRTK) on Friday, May 13 with “Outperform” rating.

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $677.37 million. The Firm is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. It currently has negative earnings. The Company’s product candidates are the antibacterials omadacycline and sarecycline.

More notable recent Paratek Pharmaceuticals Inc (NASDAQ:PRTK) news were published by: which released: “Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017” on September 19, 2017, also with their article: “Paratek’s omadacycline granted additional QIDP status in US” published on September 21, 2017, published: “Paratek Puts Skin In The Infection Game” on July 24, 2017. More interesting news about Paratek Pharmaceuticals Inc (NASDAQ:PRTK) were released by: and their article: “Paratek Pharmaceuticals: The 1 Antibiotic Stock To Buy Now” published on May 22, 2017 as well as‘s news article titled: “Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017” with publication date: September 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.